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Received 9 September 2009; received in revised form 17 November 2009; accepted 18 November 2009Abstract Meticulous characterization of human embryonic stem cells (hESC) is critical to their eventual use in cell-based
therapies, particularly in view of the diverse methods for derivation and maintenance of these cell lines. However,
characterization methods are generally not standardized and many currently used assays are subjective, making dependable
and direct comparison of cell lines difficult. In order to address this problem, we selected 10 molecular-based high-resolution
assays as components of a panel for characterization of hESC. The selection of the assays was primarily based on their
quantitative or objective (rather than subjective) nature. We demonstrate the efficacy of this panel by characterizing 4 hESC
lines, derived in two different laboratories using different derivation techniques, as pathogen free, genetically stable, and able
to differentiate into derivatives of all three germ layers. Our panel expands and refines a characterization panel previously
proposed by the International Stem Cell Initiative and is another step toward standardized hESC characterization and quality
control, a crucial element of successful hESC research and clinical translation.
© 2009 Elsevier B.V. All rights reserved.Introduction
Human embryonic stem cells, first isolated in 1998 (Thomson
et al., 1998), can differentiate into all three germ layers, and
provide novel biological systems to better understand early
human development and disease. Furthermore, they can
serve as an ex vivo source for cell-based therapies, due to
their defining characteristics—an unlimited potential for self-
renewal and the ability to differentiate into all cell types in
the adult body (Thomson et al., 1998; Reubinoff et al.,⁎ Corresponding author. Fax: +1 732 445 2063.
E-mail address: ricohen@biology.rutgers.edu (R.I. Cohen).
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doi:10.1016/j.scr.2009.11.0012000). An additional facet of hESC that is garnering more
interest is their use as in vitro models for drug discovery
and preclinical drug safety testing. Many groups have begun
high-throughput screens of small molecule libraries in hESC
to identify new bioactive compounds (Desbordes et al.,
2008), while others, in an effort to make early clinical trials
safer and more cost-effective, have used differentiated
hESC to test the efficacy and toxicity of existing and newly
developed drugs (Caspi et al., 2009). Establishing less
subjective and more quantitative standards for character-
izing hESC allows different laboratories to more easily
compare results despite culture and derivation differences
and is critical to successful clinical translation of stem cell
technologies..
93High resolution analysis of hESCSince the advent of hESC culture more than 10 years ago,
many technological advances have been made resulting in
diverse hESC culture systems. These culture systems consist
of two main components—the substrate on which the cells
grow and the culture media in which the cells are grown;
both components are important for maintaining pluripo-
tency. Initially, hESC derivation and culture were done on
mouse embryonic fibroblasts grown in media containing fetal
bovine serum (Thomson et al., 1998), thus raising the possi-
bility of cell contamination with xenopathogens (reviewed in
(Unger et al., 2008)). To eliminate the latter concern, efforts
have been made to reduce or eliminate nonhuman animal
components in the culture system and utilize completely
defined reagents. For instance, there is now extensive liter-
ature on the use of human feeder cells to support pluripotent
growth of hESC (Amit et al., 2003; Cheng et al., 2003;
Richards et al., 2002, 2003; Stojkovic et al., 2005) and
induced pluripotent stem cells (iPSC) (Unger et al., 2009).
Several new non-cell-based substrates have also been shown
to support the undifferentiated growth of hESC, including
Matrigel (Ludwig et al., 2006; Xu et al., 2001, 2005), laminin
(Beattie et al., 2005), fibronectin (Amit et al., 2004), and
vitronectin (Braam et al., 2008). There are also several new
hESC media systems that have been shown to support the
proliferation of pluripotent hESC (Ludwig et al., 2006; Chin
et al., 2009; Ellerstrom et al., 2006; Genbacev et al., 2005;
Hovatta et al., 2003; Li et al., 2005; Peiffer et al., 2008;
Vallier et al., 2005), that both eliminate nonhuman animal
sera and are completely or nearly completely defined. With
these advances in media systems and growth substrates, it is
now possible to culture cells under completely defined,
animal-free conditions that produce cells that are more
suitable for future clinical use (Ellerstrom et al., 2006; Crook
et al., 2007).
Coincident with the refinement of culture techniques,
methodologies for isolation of the inner cell mass (ICM) have
also changed. Once again, the aim has been to avoid the use
of products of animal origin for ICM isolation (Ellerstrom
et al., 2006; Heins et al., 2004; Strom et al., 2007; Turetsky
et al., 2008; van de Stolpe et al., 2005). As is the case with
different culture systems, the choice of ICM isolation tech-
nique (i.e., mechanical versus immunosurgical) may affect
the characteristics of the resulting cell line. This is especially
evident in recent data that demonstrate even when isolated
with the same method, different cell lines have varying
differentiation potentials (Wu et al., 2007; Moore et al.,
2008; Chang et al., 2008). Thus it is possible that derivation
at multiple laboratory sites under varied conditions and
using apparently insignificant variations in protocol may
result in biased differentiation potential.
Such differences in differentiation potential in turn raise
the possibility of inconsistencies in experimental results
when different cell lines are used. Even slight changes in
culturing methods may have subtly changed the undifferen-
tiated cells, making it very difficult to compare results across
different culture conditions. These changes are magnified
when studying the differentiation of hESC, a stochastic
process that is not always fully understood or controlled.
Several groups, most notably the International Stem Cell
Initiative (ISCI), have promoted standard techniques and
assays to compare hESC lines (Adewumi et al., 2007; Smith
et al., 2009; Loring and Rao, 2006). We undertook the effortof refining and expanding ISCI's panel of assays to take
advantage of new technologies that have since emerged and
to include essential cell line identification assays which were
not included in the ISCI panel. To ensure that the additional
assays are robust, reproducible, and suitable for many hESC
lines, we used them to characterize three new hESC lines
(RNJ7, 8, and 9) and compared the results to those obtained
from H9, one of the most commonly studied cell lines.
Results
Derivation of the RNJ cell lines
The need for new hESC lines that are low in passage number
and have had less exposure to nonhuman animal components
has been well documented (Amit and Itskovitz-Eldor, 2002;
Gruen and Grabel, 2006). However, several groups have
suggested that different hESC lines have distinct differenti-
ation potentials (Wu et al., 2007; Moore et al., 2008; Chang
et al., 2008), leading to even more interest in deriving new
cell lines. In this study three new hESC lines (RNJ7, 8, and 9)
were derived from clinically unusable in vitro fertilization
embryos with informed consent of the embryo donors and IRB
approval. After 4–5 passages on human foreskin fibroblasts,
the putative lines were adapted to a feeder-free culture
system using Matrigel as a substrate. All three lines have
been maintained in culture in an undifferentiated state for
over 40 passages.
Short tandem repeat analysis distinguishes unique
cell lines
Since hESC lines are not visually distinct, it is very important
to have an assay to ensure that cell lines that are cultured
concurrently are not cross-contaminated. This is particularly
important in light of recent reports indicating that many
well-established cell lines are contaminated with other cell
lines (Cabrera et al., 2006). In the present panel, the
AmpFS STR Identifiler PCR Amplification Kit (Applied Biosys-
tems) was used to determine the unique genetic signature of
each of our new cell lines, as well as that of the H9 cell line.
As expected, analysis showed that the genetic signature of
each line was unique (Fig. 1A). We also confirmed that the
genetic signature of each line did not change during
differentiation (Fig. 1A), confirming the faithful mainte-
nance of separate lines during passaging in our laboratory.
Quantitative PCR detects potential microbiological
contamination
As is the case with all cells in culture, hESC have the
potential to carry pathogens through both viral integration
into the genome and contamination of the culture media.
While there are several methods that can detect the
presence of known pathogens, a cost-effective, quantita-
tive, and sensitive assay is desirable. Using Taqman qPCR,
the genomic DNA of cultured hESC was tested for the
presence of 16 common human viral pathogens (Fig. 1B). In
order to determine the sensitivity of this assay, artificial
templates were spiked into known amounts of human
genomic DNA to identify the lowest number of copies per
94 J.C. Moore et al.genome that could be detected by this method. Less than 1
copy of viral template per human genome could be reliably
detected in 15 of the 16 pathogen assays. In all cases the
tested cell lines had a lower signal than the lowest
detectable standard for a given pathogen.In order to ensure that hESC are not contaminated with
mycoplasma, another microbiological infection commonly
found in the laboratory, we used a quantitative and sensitive
assay, capable of detecting a large number of mycoplasma
strains. As with the pathogen testing, themycoplasma testing
95High resolution analysis of hESCrelies on the creation of a standard curve from an artificial
template, allowing us to quantitate our detection limit. As
shown in Fig. 1C, all cell lines tested negative for the more
than 90 strains of mycoplasma detected by the assay.
High- and low-resolution methods for determining
karyotypic stability
For hESC to provide a representative model system for
human disease and development, they must maintain their
genetic integrity. Here we used two techniques to demon-
strate the karyotypic stability of hESC. Traditional G band
analysis was a standard low-resolution assay done at least
every 8 passages. After 39, 26, and 20 passages of RNJ7,
RNJ8, and RNJ9, respectively, no chromosomal duplications
or deletions were detected (Fig. 2A). Although G-banding is
among the most common methods for analyzing the
karyotype of hESC, it has a limited resolution. To obtain a
more global, higher resolution karyotype, we also used array
comparative genomic hybridization (aCGH). This technique
utilizes 244,000 probes that have a median spacing of 8.9 KB,
making it much more sensitive than a typical G-band analysis
with respect to regional insertions or deletions; it also allows
detection of small karyotypic changes over time (Fig. 2B).
Since this process is repeated every 8 weeks, the aCGH
results have also demonstrated that our cell lines have
retained their genetic integrity over extended periods in
culture.
Quantitating pluripotency in undifferentiated hESC
lines
To demonstrate the pluripotency of our hESC lines, we
examined their morphology, expression of pluripotent
markers, and epigenetic state. When grown on Matrigel-
coated dishes in the presence of mTeSR1, these lines grow
consistently as tightly compacted colonies, an important
morphological characteristic of hESC (Fig. 3A). Immunocy-
tochemical staining with antibodies to Oct4 and SSEA4
showed that these two markers of pluripotency were
expressed at high levels, while SSEA1 (a differentiation
marker) was not expressed (Fig. 3B). To determine the
proportion of cells expressing both SSEA4 and Oct4, cell lines
were subjected to flow cytometry. As seen in Fig. 3C, more
than 80% of cells are Oct4/SSEA4 double positive.
Another recently identified hallmark of pluripotency is the
regulatory state of the noncoding RNA XIST (Silva et al.,
2008). Using TaqMan qPCR to measure XIST expression in theFigure 1 Identification and microbiological testing of hESC lines
RNJ8, and RNJ9. Genomic DNA from each sample at the undiffe
fingerprinted using the AmpFS STR Identifiler kit. As expected the g
stage. (B) The RNJ7, RNJ8, RNJ9, and H9 cell lines do not contain
curve was generated using artificial PCR templates to determine
qPCR was then done on genomic DNA and in all cases, the resulting
a high confidence that the cells are not contaminated with the test
and H9 cell lines for more than 90 strains of mycoplasma and fou
template is shown, along with a dissociation curve. The melting
template standard, ensuring that any low-level amplification seen
product amplification.two females lines (H9 and RNJ8), we found that XIST
expression is relatively high in RNJ8, and low in H9 (Fig.
3D). Previous work by Silva et al. demonstrated that in most
cases the H9 cell lines have lost XIST expression as a
consequence of extended culture after X chromosome
inactivation. This suggests that RNJ8 cells are in an earlier
state of pluripotency than H9 cells, based on this criterion.
Large-scale gene expression analysis defines
differentiation stage and similarity of independent
hESC lines
The above assays for pluripotency compare a small subset of
markers including Oct4 and SSEA4, but some differences were
detected (e.g., XIST), necessitating a comparison of hESC lines
across the whole genome. To achieve a high-resolution and
high-throughput assay to gauge quantitatively the similarity of
the different hESC lines, we used Taqman Human Stem Cell
Pluripotency Arrays (Microfluidic Cards) from Applied Biosys-
tems. These cards contain 96 unique Taqman qPCR assays that
assess relative mRNA expression levels of markers of pluripo-
tency and differentiation using a set of probes selected by the
International Stem Cell Consortium (Adewumi et al., 2007).
For each undifferentiated cell line, at least 3 biological
repeats (from different passages) were subjected to analysis
using the Taqman Human Stem Cell Pluripotency Arrays. In
addition, at least 3 biological repeats of each cell line at the
embryoid body and neural stem cell stage were analyzed. As a
global view of relatedness, hierarchical clustering analysis
showed that all but one of the undifferentiated hESC group
together, while most of the NSC and EBs cluster in their own
respective groups (Fig. 4A). The means of all the biological
repeats were also clustered, demonstrating that the predom-
inant grouping is by cell stage, not cell line (Fig. 4B).
Immunocytochemistry and quantitative RT-PCR
assays for in vitro differentiation
Pluripotent, hESC must be able to differentiate into
derivatives of all three germ layers. In order to test this,
EBs from each line were plated and allowed to grow for
2 weeks. Immunocytochemistry for markers of differentia-
tion showed that embryoid bodies expressed α-fetoprotein
(endoderm), smooth muscle actin (mesoderm), and β-III
tubulin (ectoderm) (Fig. 5A). In addition, qPCR analysis
showed that all three lines showed substantially higher
expression of 3 markers of differentiation (α-fetoprotein
(AFP), endoderm; synaptophysin (SYP), ectoderm; and. (A) STR analysis confirms the unique genotype of H9, RNJ7,
rentiated, neural stem cell, and embryoid body stages were
enetic fingerprint of each line is independent of differentiation
detectable levels of 16 known human pathogens. A standard
the minimum number of virus copies detectable per genome.
PCR signal was smaller than the detection limit, suggesting with
ed pathogens. (C) qPCR was used to test the RNJ7, RNJ8, RNJ9,
nd to be mycoplasma free. The amplification of the artificial
point of each sample is different than that of the artificial
in the tested cell lines is due to primer dimmers and not true
Figure 2 Karyotypic stability. (A) Standard G-band analysis demonstrates that the H9, RNJ7, RNJ8, and RNJ9 cell lines have no gross
chromosomal abnormalities and have maintained their genetic integrity over at least 40 passages. (B) Array comparative genomic
hybridization provides a high-resolution verification of genetic stability and does not identify any recombination or translocation
hotspots.
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Figure 3 Pluripotency of hESC. The RNJ7, RNJ8, RNJ9, and H9 cell lines are pluripotent. (A) Compact colony morphology with
clearly defined edges is a hallmark of pluripotency. (B) Immunofluorescence for Oct4 (green), SSEA4 (red), and SSEA1 (purple)
demonstrates that most cells in a colony are positive for markers of pluripotency (Oct4 and SSEA4) while being negative for SSEA1
(marker of differentiation). The same field is shown for each cell line. (C) Each cell line was analyzed by flow to determine the
percentage of SSEA4+/Oct4+ cells. The percentage of cells that were double positive for both markers was greater than 80% in all cell
lines. FACS was done on three different passages and the data shown represent the mean±standard error of the mean. (D) The XIST
expression level for the female cell lines (H9 and RNJ8) was analyzed by qPCR. XIST expression in the H9 cells is low in both pluripotent
cells and NSCs, suggesting that even as undifferentiated cells, H9 have undergone XIST activation, and then lost expression of the
gene. However, the RNJ8 line expressed XIST even when undifferentiated, suggesting that while XIST activation has occurred in these
cells, they have not lost gene expression.
97High resolution analysis of hESCcollagen 1A1 (COL1A1), mesoderm) when normalized to their
undifferentiated counterparts (Fig. 5B).Discussion
We have identified and tested a panel of objective assays for
the detailed characterization of hESC lines. Each componentassay in the panel involves commonly used laboratory
techniques available to most academic core facilities. We
also chose sensitive qPCR-based assays when available (STR
DNA fingerprinting, taqman gene arrays), since these can be
established in core facilities with minimal training. Further-
more, when possible, we chose to use a quantitative
approach, such as constructing standard curves to determine
the lowest detectable level of pathogen or contaminant
Figure 4 Genome-wide analysis for pluripotency. The gene expression profiles of the RNJ7 (passages 16, 17, and 22), RNJ8 (passages
14, 20, and 21), RNJ9 (passages 13, 16, and 18), and H9 (passages 34, 45, and 49) cell lines were analyzed by large-scale qPCR. (A)
Hierarchical clustering analysis of individual samples shows that with the exception of a few outliers the undifferentiated samples
group together, while most of the NSC and EBs cluster in their own respective groups. (B) When biological repeats are averaged,
hierarchical clustering analysis shows that the undifferentiated samples group together and most of the NSC and EBs also cluster
together in their own distinct groups.
98 J.C. Moore et al.template detected in each assay. Without a positive control
and a measure of sensitivity, these assays would not be as
valuable in following cultures over time.
The assays demonstrated the unique identity of the cell
lines and assessed some aspects of their pluripotent state.
General adoption of standard characterization assays such as
those used in this study would address the problem of
variability in hESC derivation, culture, expansion, and
differentiation methods and allow comparison of experimen-
tal results generated by different laboratories. The panel is
also useful for routine cell line quality control; the frequency
we recommend for each test (based on a cost-benefitanalysis) is shown in Table 1. Since these assays are relatively
cost-effective and require minimal labor, they can be
repeated over passaging to ensure consistency. Other groups,
including the ISCI, have previously proposed first generation
assays to characterize pluripotent cells (Adewumi et al.,
2007; Loring and Rao, 2006); the present panel is a refined
and expanded version of the ISCI panel and provides quan-
titative data whenever possible. In selecting this character-
ization panel, emphasis was placed on the quantitative
aspect of the assays as well as the increased resolution of the
molecular techniques, with the aim of providing results that
are more objectively interpreted.
Figure 5 In vitro differentiation. Embryoid bodies were generated from the RNJ7, RNJ8, RNJ9, and H9 cell lines and analyzed for
derivatives of each of the three germ layers. (A) Immunocytochemical staining demonstrates the presence of endoderm (alpha-
fetoprotein; AFP), mesoderm (smooth muscle actin; SMA), and ectoderm (β-III tubulin; TUJ-1). (B) qPCR was also used to assay for
derivatives of endoderm (alpha-fetoprotein; AFP), mesoderm (collagen type 1A1; col1A1), and ectoderm (synaptophysin; SYP).
99High resolution analysis of hESCThere are a number of important differences between this
panel and previously used assays (summarized in Table 2); these
include STR DNA fingerprinting instead of SNP assays, substitu-
tion of G-band karyotyping methods with array CGH, and
measurement of transcription factors (instead of cell surface
markers) involved in the maintenance of pluripotency using
FACS, rather than qualitative immunocytochemistry, and gene
expression microfluidic cards (rather than Northern blots and
microarrays). Moreover, qPCR (in addition to immuno-cytochemistry) is used to assess differentiation into ectoderm,
mesoderm, and endoderm lineages.
Since positive and unambiguous identification of cell lines is
a key aspect of characterization and crucial prior to patient
therapies, we chose to substitute SNP arrays with short tandem
repeat fingerprinting using a commercially available kit.
Advantages of this kit include the small amount of DNA required
(only 1 ng of DNA is required), the inclusion of CODIS-
compatible markers for comparison with other kits, the ability
Table 1 Recommended Frequency of Testing
Assay Initial Every 4 passages Every 8 passages Every 12 passages Every 24 passages
DNA Fingerprint ✓ ✓
Human Viruses ✓ ✓
Mycoplasma ✓ ✓
Karyotype ✓ ✓
aCGH ✓ ✓
SSEA4+/Oct4+ (ICC) ✓ ✓
SSEA4+/Oct4+(FACS) ✓ ✓
XIST expression (female only) ✓
(if applicable)
✓
(if applicable)
Taqman human stem cell pluripotency
arrays for Pluripotency
✓ ✓
IF for Endoderm ✓ ✓
IF for Mesoderm ✓ ✓
IF for Ectoderm ✓ ✓
qPCR for Endoderm ✓ ✓
qPCR for Mesoderm ✓ ✓
qPCR for Ectoderm ✓ ✓
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ing equipment (such as that found in most core facilities), and
the ability to run all markers in a single PCR. We recently
collaborated with others to demonstrate that the AmpFS STR
Identifiler kit provides results consistent with SNP assays (Fang
et al., in preparation), which could be run at higher resolution
but are more difficult to scale for routine laboratory screening.
Another important aspect of characterization is screening for
potential human viral pathogens which is not only for the safety
of laboratory workers but for the safety of future cell-based
therapies. Contamination may come from source material or be
introduced during laboratory handling. The method included in
our panel is based on quantitative PCR screening for 16 common
viral human pathogenswhich have been previously suggested by
the International Stem Cell Initiative (Adewumi et al., 2007).
Other methods for screening for potential pathogens have
included screening for antibodies for 13 common human
pathogens present in the blood of the embryo donors (Crook
et al., 2007), PCR screening of feeder cells used to derive hESC
for 15 common human pathogens (Genbacev et al., 2005), and
PCR screening of resulting hESC lines (WiCell National Stem Cell
Bank). One of the drawbacks of these PCR screens is their
unknown sensitivity. The sensitivity of our assay, however, wasTable 2 Improved Characterization Panel
Property Commonly-Used or A
Establish/confirm identity SNP
Contamination with Human Viruses Antibody detection
Mycoplasma qPCR (single species
Karyotype G-band Analysis
Pluripotency ICC
-
Northerns/Microarra
ICC for Endoderm
ICC for Mesoderm
ICC for Ectodermempirically determined through the use of uninfected human
DNA from a commercial source and artificial oligonucleotide
templates designed from target viral sequences. In many cases,
we could detect fewer than 0.01 copies of virus per genome and
in all caseswedetectedas fewas 1 copyper genome.This allows
accurate assessment of assay sensitivity and the likelihood of
infection, with the added benefit that the artificial virus
templates did not require the presence of infectious virus in
the laboratory, a potential hazard toworkers aswell as cultures.
In addition to testing for viral contamination, it is also very
important to ensure that cell cultures are not infected with
mycoplasma. The presence of mycoplasma in a culture facility
and its ability to quickly infect cultures handled in the same
biosafety hood or growing in the same incubator are major
concerns. Previous studies have shown that the presence of
mycoplasma affects the growth, morphology, and metabolism
of cultured cells (Drexler and Uphoff, 2002; Markoullis et al.,
2009). As with the human virus assay, themycoplasma assaywe
adopted provides high sensitivity and good positive controls,
eliminating the possible introduction of mycoplasma from kit
components. In addition, the assay we used detects more than
90 individual species of mycoplasma, making it one of the most
comprehensive kits available commercially.lternative Assay Recommended Assay
STR DNA fingerprint
or outsourced virology lab qPCR
) qPCR (multiple species)
aCGH
FACS
XIST expression
y Taqman human stem cell
pluripotency arrays cards
qPCR for Endoderm
qPCR for Mesoderm
qPCR for Ectoderm
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robust cell lines. This is of particular concern when clinically
unusable embryos with morphological and/or genetic abnor-
malities are used for stem cell derivation. Furthermore,
several groups have shown that some hESC lines are prone to
specific chromosome deletions or amplifications, while others
have shown that the method and number of passages can
affect karyotypic stability (Draper et al., 2004; Maitra et al.,
2005; Rosler et al., 2004).While G-bandingmethods can verify
the absence of large chromosomal translocations, duplica-
tions, and deletions in a limited number of cells, other more
subtle changes can only be detected by more sensitive
molecular assays such as aCGH. For example, some specific
common mutations have been detected by aCGH including
duplication at 20q11.21 (Spits et al., 2008; Werbowetski-
Ogilvie et al., 2009). When performed at frequent intervals
(e.g., every 8 passages) aCGH can detect recombination or
translocation hotspots specific to a given cell line, providing
objective, molecular-based results of genome integrity.
A defining feature of hESC is their pluripotency. One
measure of pluripotency is the epigenetic state of cells. In
particular, female cell lines must undergo inactivation of one
of the two X chromosomes (X-chromosome inactivation or
XCI) during the initial stages of differentiation. The noncod-
ing RNA XIST is regulated during XCI and has been proposed to
participate in the mechanism (Silva et al., 2008). Silva et al.
proposed three states of XCI which suggest the level of
pluripotency of a culture. The first class (Class I) is found in
hESC that are still able to undergo XCI upon differentiation.
Class II refers to cells that have already undergone XCI
despite their apparent “stemness” and Class III describes
cells that have undergone XCI and have then lost XIST RNA
expression over extended culture. Assaying for XIST ex-
pression in female cultures allows determination of a key
element of the epigenetic state of chromatin in relation to
differentiation and can give a measure of the state of
pluripotency. Since XIST is easily assayed using a standard
TaqMan probe set, we believe it will be helpful in char-
acterizing female hESC cultures.
Pluripotency was also assessed by two additional assays,
FACS for SSEA4/Oct4 and Taqman Human Stem Cell
Pluripotency Arrays, two methods that provide a quanti-
tative measure of pluripotency. While one or the other of
these assays has been used previously to assess pluripotency
(Peiffer et al., 2008; Vallier et al., 2005; Chan et al., 2008;
Gibson et al., 2009; Lavon et al., 2008), they complement
each other and are even more effective when used together.
First, FACS for SSEA4+/OCT4+ cells measures the expression
levels of two markers that are known to be highly expressed
in undifferentiated stem cells. When evaluating expressed
proteins in cells, we favor FACS over traditional immunocy-
tochemistry. Although traditional immunocytochemistry is
still necessary to validate antibodies and can be useful in
determining which cells express certain markers on an
individual cell basis, we chose flow cytometry, since a
more quantitative result can be used to judge minor
variations among cell lines. The second assay, the Taqman
Human Stem Cell Pluripotency Array (developed by AB, based
on the work of the International Stem Cell Initiative)
(Adewumi et al., 2007), has the advantage of measuring a
large subset of pluripotency markers, but only at the RNA
level. When three independent biological repeats of eachcell line at each stage of differentiation were clustered,
most hESC clustered in a single group, while the NSC and EB
stages clustered in roughly their own groups (Fig. 4A).
However, there were very few samples that clustered
outside their respective groups, such as one biological repeat
of RNJ8 (far left in Fig. 4A), suggesting that this assay is
sensitive enough to identify suboptimal cultures, such as
those with increased spontaneous differentiation. Although
outliers were present when comparing individual biological
repeats clustering analysis of the means of the biological
repeats demonstrated the relatedness of each stage of
differentiation regardless of the cell line. A combination of
these two assays provides a detailed picture of the
uniformity of the starting material before differentiation
protocols are used.
The final cohort of tests focused on the ability of hESC to
differentiate into all three germ layers. This has typically
been achieved through teratoma formation in vivo and
embryoid body formation in vitro followed by immunocyto-
chemistry (Thomson et al., 1998; Reubinoff et al., 2000;
Carpenter et al., 2003). While teratoma formation may be the
gold standard for determining pluripotency, we have
attempted to identify assays that are less time consuming,
less expensive, and more quantitative. In this study we
attempted to use EB formation followed by qPCR to
quantitatively determine the potential for differentiation.
However, the number of repeats necessary to gain statistically
significant results was quite high, making this assay too
complex and impractical. In every EB sample tested, it was
easy to detect markers from each germ layer, but their levels
varied widely, reflecting the stochastic nature of hESC
differentiation. While this assay may not be suitable for
quantitatively determining the differentiation potential of a
given cell line, it requires very little starting material and can
still verify the ability to form derivatives of the ectoderm,
mesoderm, and endoderm. In order to verify our qPCR results
we also used antibodies to smooth muscle actin, alpha-
fetoprotein, and β-III tubulin to show the expression of
markers of each germ line by immunocytochemistry in EBs.
Particularly in light of the fact that our qPCR method to assess
pluripotency was not successful, newly derived, completely
uncharacterized lines may still need to be used in teratoma
formation assays to prove their initial pluripotency.
To conclude, we have built on, refined, and expanded a
previously proposed panel for characterization and quality
control of hESC. Although other assays may be chosen for
reasons specific to each laboratory, the assays we have used
here have the advantage of producing objective rather than
subjective results. We speculate that these assays will also
be suitable for characterization of iPSC, although additional
tests to determine the extent of reprogramming in those
cells may be necessary.Materials and methods
Source embryos
Embryos were obtained from consenting patients undergoing
infertility treatment at the Institute for Reproductive
Medicine and Science at Saint Barnabas Medical Center
(IRMS-SBMC, Livingston, NJ). The 3 cell lines characterized in
102 J.C. Moore et al.this study were derived in January and February of 2008;
during this period, a total of 23 clinically unusable fresh
donated embryos were plated as described below. The
research protocol was approved by the Internal Review Board
of SBMC and allowed the use of nonviable embryos (i.e.,
clinically unusable embryos or those excluded from intra-
uterine transfer and cryopreservation for future use) for
derivation of stem cells. The developmental and morpho-
logical characteristics of each embryo were noted, before
each was placed in 2.5 ml Global culture medium (IVF Online,
Guilford, CT, USA) supplemented with 5% human serum
albumin (HSA; Sage, Pasadena, CA) in a 2.5-ml polystyrene
tube; the tube was capped tightly to prevent CO2 exchange
and a subsequent increase in medium alkalinity. The capped
tubes were then placed in a battery-operated portable
incubator (Agtech, Manhattan, KS, USA) equipped with two
tube holders, prewarmed to 37 °C, and were transported
from the IRMS IVF laboratory to the stem cell laboratory,
located in a separate facility. In total, the embryos spent
approximately 1 h in transit during which the temperature
was kept at 37 °C. On arrival in the stem cell laboratory, the
embryos were recovered from the tubes and placed in 50- to
100-μl microdrops of HSA-supplemented Global medium
under mineral oil, and the dishes were placed in an incubator
at 37 °C, in a humidified atmosphere of 5% CO2 until mani-
pulation for inner cell mass (ICM) isolation.Isolation of the inner cell mass
The inner cell masses were isolated using immunosurgery
(RNJ8) (Thomson et al., 1998; Kim et al., 2005; Sullivan et al.,
2007) or a novel mechanical isolation method (RNJ7 and
RNJ9). The mechanical isolation involved micromanipulation
on an inverted microscope equipped with a double microtool
holder and a heated stage. Three types of glass microtools
were used: a holding pipette, a “spear” or needle, and a
biopsy needle with an inner diameter of about 45 μm. The
fully intact blastocyst was placed in a 20-μl drop of HTF-Hepes
medium (IVF Online) supplemented with 10% HSA; the embryo
was held firmly by a holding pipette on the left; the needle
was brought in from the right; the zona was penetrated on one
side and the spear was forced through the polar trophecto-
derm (or the pole opposite to that of the ICM) andmade to exit
both the trophectoderm and the zona on the other side. The
blastocyst was released from the holding pipette while held on
the needle. The holding pipette was then used to rub against
the zona/trophectoderm segment isolated on the spear. Once
the embryo fell off the needle, a large slit in both the zona
pellucida and the trophectoderm had been created. The spear
was then replaced with a biopsy pipette. The partially
dissected blastocyst was picked up by the holding pipette
and the “flap”was forced open using the biopsy pipette. If the
blastocyst collapsed, medium was injected into the collapsed
cavity in order to expand it artificially. The ICM was then
located and gently aspirated into the biopsy pipette.
Following isolation, the ICM was released back into the
microdrop, away from the holding pipette. The remaining
blastocyst trophectoderm was also released from the holding
pipette. The dish was removed to the warm surface of the
laminar flow hood and the isolated ICM was picked up using a
hand-pulled, polished, HSA-coated Pasteur pipette. It wasthen placed immediately onto a monolayer of feeder cells as
described below.
Culture media and systems
Two culture strategies were used in the derivation and
expansion process. Initially, isolated ICMs were placed on
feeder cell monolayers consisting of mitotically inactivated
newborn human foreskin fibroblast cells (American Type
Culture Collection, Manassas, VA, USA) in chemically defined
medium (CDM; Invitrogen, Carlsbad, CA) supplemented with
40 ng/ml basic fibroblast growth factor (bFGF; Invitrogen). A
day following transfer to the monolayers, the ICM was
checked for attachment. Once attachment was established,
medium was exchanged daily until a cluster of cells
developed—typically after 4 days. Between Day 5 and Day
7, the colony was carefully lifted (in whole) and placed onto
new feeder cells (for feeder cell preparation, see (Richards
and Bongso, 2006)). This was to ensure an optimal culture
environment for the proliferating cells and to separate the
putative stem cells from any remaining trophectoderm cells.
The putative stem cell colony was cultured for an additional
7 days to allow further proliferation while the medium was
exchanged daily.
Once the colony reached an approximate diameter of
2–3 mm with a clearly defined perimeter, it was dissected
into two pieces using a tool prepared from a solid glass rod,
pulled on a micropipette puller (Narishige Co., Ltd, Tokyo,
Japan), and bent on a microforge (Narishige Co., Ltd) at
roughly 50 mm from the tip at an angle of 45°. The pieces
were then placed onto new feeder cells, thus completing the
first passage of putative stem cells. Two more passages were
carried out, each time dividing colonies into 2–4 pieces until
roughly 8–15 colonies were obtained. At that point, the cells
were switched to new culture conditions, eliminating the
feeder cells and using mTeSR1 medium (Stem Cell Technol-
ogies, Vancouver, BC, Canada) in dishes coated with hESC-
qualified Matrigel (BD Biosciences, Bedford, MA, USA).
hESC culture
Undifferentiated H9 (WiCell, Madison, WI) and the newly
isolated lines (RNJ7, RNJ8, and RNJ9) were propagated by
enzymatic digestion on Matrigel in defined medium (Ludwig et
al., 2006; Moore et al., 2008). Spontaneous differentiation
(based onmorphology) occurred in less than 5% of the colonies.
Cells were passaged every 7 days at a splitting density of 1:6 to
1:10, so that the resulting cultures were 80–90% confluent on
the day of passage. Once cells were loosened from the culture
dish with Dispase (BD Biosciences) and washed with DMEM/
F12, they were gently scraped to remove them completely
from the dish and to break them into pieces. These pieces
were transferred to hESC-qualified Matrigel (BD Biosciences)-
coated plates and mTeSR1 medium (Stem Cell Technologies)
and the medium was replenished daily.
Embryoid bodies were generated as described previously
(Thomson et al., 1998; Moore et al., 2008). Briefly, cells
were treated with Dispase as described above. Following
scraping, the pieces were suspended in ultralow attachment
dishes (Corning) in differentiation medium [DMEM/F12
(Invitrogen) supplemented with nonessential amino acids
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medium was changed every other day, embryoid bodies were
plated on gelatin-coated dishes (Corning) and grown in the
same medium.
Differentiation into neural stem cells and neuronally re-
stricted precursors was induced by a two-step protocol using a
slightly modified adherent monolayer method as first pub-
lished by Smith and co-workers (Nat et al., 2007; Ying et al.,
2003). In the initial step, undifferentiated hESC at 80–90%
confluence were preconditioned for 1 day with Neural Induc-
tion Medium (NIM, which consisted of a 1:1 ratio of DMEM/F12
and Neuralbasal media containing 1X B27 (without retinoic
acid) and 1X N2 supplement (all reagents from Invitrogen)).
After 24 h the preconditioned cells were passaged using
1 U/ml Dispase and transferred to dishes coated with one-
quarter the recommended concentration of Matrigel (1/4MG)
for hESC, at a passaging ratio of 1:3 and grown for 3 more days
in NIM. On the fifth day after induction, the medium was
changed to Neural Precursor Medium (NPM). NPM is a 1:1 ratio
of DMEM/F12 and Neuralbasal media that contains 0.5X B27
and N2, as well as 20 ng/ml bFGF (Peprotech). When the cells
grown in NPM reached 90–100% confluent, theywere passaged
1:3 on 1/4MGwithmedium changes every other day. After the
second passage in NPM, the cells were usually nearly 90% SOX2
and Nestin positive and Oct4 negative, and are now named
neural stem cells (NSC). After at least 2 weeks as NSCs,
differentiation into neuronally restricted precursors could be
induced by withdrawal of FGF and addition of 10 ng/ml brain-
derived neurotrophic factor (BDNF, Peprotech). Growth in this
medium for 7–10 days resulted in the formation of long
processes, small cell bodies, and the expression of β-III
tubulin, characteristic of differentiating neurons and are
referred to as neuronally restricted precursors (NRPs).
Karyotyping
To assay for chromosomal integrity, all four hESC lines were
karyotyped by G-banding every 8 passages by Cell Line
Genetics (Madison, WI).
Array CGH
Genomic DNA was isolated from each of the 4 undifferenti-
ated cell lines using the DNA easy kit from Qiagen and 3 μg of
each was fragmented and labeled with Cy3 according to the
Agilent protocol. Apparently normal male and female DNA
was obtained from the Rutgers University Cell and DNA
Repository to use as controls. The sample and controls were
processed and analyzed by the Rutgers Bionomics Research &
Technology Center following the manufacturer's instructions
on the Agilent 244K microarray chip (G4411B).
Immunocytochemistry
Cells grown on coverslips were fixed with 4% paraformalde-
hyde in phosphate-buffered saline, pH 7.4 (PBS), at room
temperature for 15 min, washed in PBS, and blocked and
permeabilized for 1 h with blocking buffer (PBS containing 4%
normal goat serum and 0.1% Triton X-100). Incubation with
primary antibody diluted in blocking buffer was done at the
following concentrations—Oct4 (Millipore, MAB 4401) at0.5 μg/ml; SSEA4 (Millipore MAB 4304) at 1.0 μg/ml; SSEA1
(Millipore MAB 4301) at 1.0 μg/ml; Sox2 (Millipore AB 5603)
at 1.0 μg/ml; Nestin (Millipore MAB 5326) at 0.5 μg/ml; and
TUJ1 (Aves TUJ-S) at 1.0 μg/ml. After 3 washes with PBS, the
coverslips were incubated with AlexaFluor-conjugated sec-
ondary antibodies (Invitrogen) at 1:500 in blocking buffer at
room temperature for 1 h, mounted, and visualized by
fluorescence microscopy.
Ampfℓ STR Identifiler PCR amplification kit
DNA from the RNJ7, RNJ8, RNJ9, and H9 cell lines in their
pluripotent, embryoid body, and neural stem cell stages was
isolated from 500 000 cells using the DNeasy Blood and Tissue
kit from Qiagen. DNA (0.1 ng/μl) from each sample was
amplified by PCR as described in the AmpfℓSTR protocol.
This assay detects variations in 15 STR loci (including the 13
found in the CODIS set) as well as amelogenin in a single tube.
Resulting PCR products were separated using capillary
electrophoresis and detected with an ABI Prism 310 genetic
analyzer.
Mycoplasma
Approximately 2 million cells were collected from each
culture sample via an enzymatic digestion with Accutase
(Stem Cell Technologies). Genomic DNA was isolated using
the DNeasy Blood and Tissue kit from Qiagen as per the
manufacturer's instructions and diluted with nuclease-free
water to 5 ng/μl. The Mycoplasma Detection Assay kit (AB)
was utilized for the screening by quantitative real-time PCR
(qPCR). An artificial mycoplasma template provided in the kit
was diluted in human genomic DNA from Promega (G304A)
and used as a positive control. Samples lacking DNA templates
were also run to ensure that any amplified products were the
result of the presence of mycoplasma DNA. The PCR and
cycling conditions were completed as described in the
manufacturer's instructions.
Pathogen testing
Cell collection and DNA preparation were done as described
for mycoplasma screening. In order to quantitatively deter-
mine the amount of pathogen DNA in each sample, standard
curves for each of the pathogens (HTLV1, HTLV2, SV40,
HPV16, HCV, HIV1, HIV2, HHV7, HBV, BK, JC, EBV1, EBV2,
CMV, and adenovirus) were prepared using oligonucleotide
artificial templates as provided by Applied Biosystems. Serial
dilutions of each artificial template from 1000 to 0.001 copies
of artificial template per genome were diluted in human
genomic DNA from Promega (G304A). PCR and cycling
parameters were done as described in the manufacturer's
instructions. For each sample tested, the controls included
were no template control, a negative control that contained
only the control DNA, and a positive PCR control for 18S RNA.
Fluorescence-activated cell sorting (FACS)
One million cells per cell line at 3 different passages were
collected using Accutase. The cells were fixed in 2% para-
formaldehyde at room temperature for 15 min. After
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were permeabilized by resuspending in 0.5% saponin in BSA/
PBS/Azide buffer (1X PBS, 0.1 M sodium azide, 0.5% BSA) for
10 min at room temperature. Cells were then washed with
PBS and resuspended in permeabilization buffer containing
primary or directly labeled antibodies, incubated at room
temperature for 30 min, and washed twice with permeabi-
lization buffer. Secondary antibody staining (Invitrogen
AlexaFluor dyes 1:500) was done for 30 min in the dark.
The cells were then washed twice with permeabilization
buffer, once with BSA/PBS/Azide buffer, resuspended in
BSA/PBS/Azide buffer, and analyzed on a FACS Calibur
(Becton Dickinson, Franklin Lakes, NJ, USA). The BD software
program CellQuest was used for data acquisition and
analysis. GFP and/or 488 fluorescence intensity was mea-
sured in the FL1 channel and phycoerythrin and/or 594
fluorescence intensity was measured in the FL2 channel.
RNA isolation and reverse transcription
One to two million cells from each cell line and differenti-
ation stage were collected using Accutase and lysed in TRIzol
(Invitrogen) according to the manufacturer's instructions.
RNA (4 μg) was reverse-transcribed using the High Capacity
cDNA Reverse Transcription Kit from Applied Biosystems
following the manufacturer's protocol.
Taqman human stem cell pluripotency arrays
Using the cDNA generated above, 100 ng of each sample was
mixed with 50 μl of 2X Universal PCR Master Mix and brought
to a final volume of 100 μl with nuclease-free water. This
mixture was then loaded onto the Human Stem Cell
Pluripotency Array from Applied Biosystems and PCR was
done according to the conditions described by the manufac-
turer. Data analysis was performed using BioConductor/R
(http://www.bioconductor.org).
Taqman gene expression assays
Taqman gene expression assays (Applied Biosystems) were
run according to the manufacturer's instructions. The
following primer sets from Applied Biosystems were used:
AFP, Hs00173490_m1; COLA1A Hs00164004_m1; SYP,
Hs00300531_m1; XIST, Hs00300535_s1; 18s RNA, 4352930E;
and GAPDH RNA, 4333764F. Briefly, 50 ng of total cDNA was
added to 1 μl of each Gene Expression Assay along with 10 μl
of 2X Gene Expression Master Mix and brought to a final
volume of 20 μl using nuclease-free water. These samples
were run using the thermal cycling conditions provided in the
protocol. Relative expression was determined using the ΔΔCt
method, using GAPDH or 18s RNA expression as endogenous
control.
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